EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announces today that Merck & Co. Inc (“Merck”) published a research paper citing EnWave’s freezeREV® process as a viable manufacturing alternative to vial-based lyophilization for vaccines and biologics. The research article entitled “Evaluation of Microwave Vacuum Drying as an Alternative to Freeze-Drying of Biologics and Vaccines: The Power of Simple Modeling to Identify a Mechanism for Faster Drying Times Achieved with Microwave” was published in the January 19, 2021 edition of PharmSciTech, the official journal of the American Association of Pharmaceutical Scientists.
Merck’s nine-month evaluation used a lab-scale freezeREV® unit manufactured by EnWave specifically for the dehydration of pharmaceutical products. The goal of the study was to determine the uniformity and repeatability of Microwave Vacuum Drying (MVD) when used to dry liquid vaccines in vials. This evaluation is the first of its kind to scientifically document the efficacy of microwave-vacuum drying, more specifically freezeREV®, for the drying of vaccines.
The authors of the research article note that both the global pandemic and the rapid spread of COVID-19 have emphasised the need for accelerated vaccine development and on-demand, flexible manufacturing options. The published evaluation results stated that “Microwave vacuum drying serves as a faster alternative to freeze drying of biologically active materials such as vaccines, proteins, and microorganism cultures”. Data from the study shows that EnWave’s freezeREV® process reduces drying cycle times by 80% to90% while maintaining product activity and stability when compared to lyophilization. Lyophilization drying times are seen as a significant bottleneck for vaccine manufacturing. The research article also confirmed that EnWave’s freezeREV® process demonstrates “comparability between EnWave’s freezeREV® and freeze-dried samples” for drying uniformity and repeatability. The significant decrease in drying times was also accompanied by increased manufacturing flexibility.
Merck has been an EnWave research partner since 2015.
EnWave plans to continue collaborating with GEA Lyophil through a Joint Development Agreement to further refine its freezeREV® technology to potentially benefit Merck’s ongoing work regarding vaccine dehydration.
The full research article can be found at Springer Link.
About EnWave
EnWave Corporation, a Vancouver-based advanced technology company, has developed a Radiant Energy Vacuum (“REV™”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV™ technology, shortening the time from harvest to high-quality, marketable cannabis products.
REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors, including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with innovative, disruptive companies in multiple verticals for the use of REV™ technology. The company has signed over forty royalty-bearing licenses to date in twenty countries world-wide. In addition to these licenses, EnWave established a Limited Liability Corporation, NutraDried Food Company, LLC, to manufacture, market and sell all-natural dairy snack products in the United States, including the Moon Cheese® brand.
EnWave has introduced REV™ as a disruptive dehydration platform in the food and cannabis sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently offers two distinct commercial REV™ platforms:
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing, are forward-looking statements. All third-party claims referred to in this release are not guaranteed to be accurate. All third-party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Merck’s nine-month evaluation used a lab-scale freezeREV® unit manufactured by EnWave specifically for the dehydration of pharmaceutical products. The goal of the study was to determine the uniformity and repeatability of Microwave Vacuum Drying (MVD) when used to dry liquid vaccines in vials. This evaluation is the first of its kind to scientifically document the efficacy of microwave-vacuum drying, more specifically freezeREV®, for the drying of vaccines.
The authors of the research article note that both the global pandemic and the rapid spread of COVID-19 have emphasised the need for accelerated vaccine development and on-demand, flexible manufacturing options. The published evaluation results stated that “Microwave vacuum drying serves as a faster alternative to freeze drying of biologically active materials such as vaccines, proteins, and microorganism cultures”. Data from the study shows that EnWave’s freezeREV® process reduces drying cycle times by 80% to90% while maintaining product activity and stability when compared to lyophilization. Lyophilization drying times are seen as a significant bottleneck for vaccine manufacturing. The research article also confirmed that EnWave’s freezeREV® process demonstrates “comparability between EnWave’s freezeREV® and freeze-dried samples” for drying uniformity and repeatability. The significant decrease in drying times was also accompanied by increased manufacturing flexibility.
Merck has been an EnWave research partner since 2015.
EnWave plans to continue collaborating with GEA Lyophil through a Joint Development Agreement to further refine its freezeREV® technology to potentially benefit Merck’s ongoing work regarding vaccine dehydration.
The full research article can be found at Springer Link.
About EnWave
EnWave Corporation, a Vancouver-based advanced technology company, has developed a Radiant Energy Vacuum (“REV™”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV™ technology, shortening the time from harvest to high-quality, marketable cannabis products.
REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors, including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with innovative, disruptive companies in multiple verticals for the use of REV™ technology. The company has signed over forty royalty-bearing licenses to date in twenty countries world-wide. In addition to these licenses, EnWave established a Limited Liability Corporation, NutraDried Food Company, LLC, to manufacture, market and sell all-natural dairy snack products in the United States, including the Moon Cheese® brand.
EnWave has introduced REV™ as a disruptive dehydration platform in the food and cannabis sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently offers two distinct commercial REV™ platforms:
- nutraREV® which is a drum-based system that dehydrates organic materials quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour; and,
- quantaREV® which is a tray-based system used for continuous, high-volume low-temperature drying.
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing, are forward-looking statements. All third-party claims referred to in this release are not guaranteed to be accurate. All third-party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
